U.S. Markets close in 2 hrs 10 mins
  • S&P 500

    3,620.59
    -19.88 (-0.55%)
     
  • Dow 30

    28,979.25
    -246.36 (-0.84%)
     
  • Nasdaq

    10,701.30
    -36.20 (-0.34%)
     
  • Russell 2000

    1,695.14
    +20.20 (+1.21%)
     
  • Crude Oil

    79.97
    -1.26 (-1.55%)
     
  • Gold

    1,670.00
    +1.40 (+0.08%)
     
  • Silver

    19.03
    +0.32 (+1.73%)
     
  • EUR/USD

    0.9792
    -0.0027 (-0.2742%)
     
  • 10-Yr Bond

    3.7480
    +0.0010 (+0.03%)
     
  • Vix

    30.35
    -1.49 (-4.68%)
     
  • GBP/USD

    1.1142
    +0.0019 (+0.1671%)
     
  • USD/JPY

    144.7420
    +0.2990 (+0.2070%)
     
  • BTC-USD

    19,661.50
    +228.62 (+1.18%)
     
  • CMC Crypto 200

    448.83
    +5.40 (+1.22%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

·1 min read
Spero Therapeutics, Inc.
Spero Therapeutics, Inc.

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022 financial results and provide an update on its business and pipeline.

To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13731565. The audio webcast can be accessed under “Events and Presentations” in the Investor and Media section of the Company’s website at www.sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.

  • Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.

  • Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat multi-drug resistant Gram-negative infections in the hospital setting.

  • Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact: 
Ted Jenkins
Vice President, Investor Relations and Strategic Finance
TJenkins@sperotherapeutics.com
(617) 798-4039

Media Inquiries: media@sperotherapeutics.com